Longbio Pharma key facts
as of Oct 2026- Manufacturer of antibody-based biologics intended for autoimmune and allergic diseases.
- Longbio Pharma is valued at approximately $277.8M as of Oct 2026 (last reported valuation).
- It has raised $76.7M; the latest was IPO in Aug 2025.
- Notable investors include Qiming Venture Partners, Oriental Fortune Capital, Highlight Capital, Shanghai Lingang Economic Development, Ancheng Capital — 13 tracked in total.
- Status: In IPO Registration.
Longbio Pharma's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Longbio Pharma: the Monday email on marks, rounds and moves
Longbio Pharma funding rounds
No funding rounds for Longbio Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Longbio Pharma
13+Membership and data by Private Market View
Longbio Pharma valuation
Longbio Pharma's last reported valuation was $278 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Longbio Pharma investors
13 investors are on record for Longbio Pharma, including Qiming Venture Partners, Oriental Fortune Capital, Highlight Capital and Shanghai Lingang Economic Development.
About Longbio Pharma
Manufacturer of antibody-based biologics intended for autoimmune and allergic diseases. The company's platform brings drugs such as monoclonal antibody drugs targeting the complement and IgE pathways to both domestic and international markets, offering affordable and high-quality bio-medicines, enabling patients to access more effective and targeted therapies.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Employees
- 67
- Website
- longbio.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.